| 中文名称 | MAY-262611 |
| 英文名称 | MAY-262611 |
| CAS号 | 1123231-07-1 |
| 分子式 | C20H22N4 |
| 分子量 | 318.42 |
| EINECS号 | 604-604-1 |
| 沸点 | 544.8±42.0 °C(Predicted) |
| 密度 | 1.169±0.06 g/cm3(Predicted) |
| 溶解度 | DMF:30mg/mL; DMSO:30mg/mL;乙醇:50mg/mL;乙醇:PBS (pH 7.2) (1:1): 0.5 mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 10.13±0.29(Predicted) |
| 颜色 | 浅黄至黄色 |
EC50: 0.63 μM (β-Catenin)
WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility.
WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β -catenin pathway and most likely through inhibition of Dkk-1.